Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas Meeting Abstract
| Authors: | Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Wang, M. L.; Arnason, J. E.; Mehta, A.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; Solomon, S. R.; Ghosh, N.; Albertson, T.; Garcia, J.; Kostic, A.; Li, D.; Kim, Y.; Siddiqi, T. |
| Abstract Title: | Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Start Page: | 241 |
| Language: | English |
| ACCESSION: | WOS:000518218500584 |
| DOI: | 10.1182/blood-2019-127508 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 626 -- Source: Wos |
